We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Novel Diagnostic Test Developed for Sickle Cell Disease

By LabMedica International staff writers
Posted on 08 Sep 2014
Print article
Image: Scientists have developed a simple new test for sickle cell disease that provides results in just 12 minutes and costs as little as USD 0.5 — far simpler, faster, and cheaper than current tests (Photo courtesy of Dr. A. Kumar and Harvard University).
Image: Scientists have developed a simple new test for sickle cell disease that provides results in just 12 minutes and costs as little as USD 0.5 — far simpler, faster, and cheaper than current tests (Photo courtesy of Dr. A. Kumar and Harvard University).
Researchers have developed a simple, rapid, low-cost test for sickle cell disease (SCD) that could enable large-scale global screening also of children in underprivileged regions, such as those in Africa and India.

A team led by Harvard University (Cambridge, MA, USA) postdoctoral fellow Ashok Kumar, PhD, and Prof. George Whitesides have developed a low-cost, novel test for SCD that provides results in just 12 minutes. “The tests we have today work great, they have a very high sensitivity,” said Dr. Kumar, “But the equipment needed to run them costs in the tens of thousands of dollars, and they take hours to run. That’s not amenable to rural clinics, or even some cities, where the medical infrastructure isn’t up to the standards we see in the US.” Although extensive analysis will be needed to determine whether the test is accurate enough to use in the field, when run against over 50 known clinical samples — 26 positive and 26 negative — it showed good sensitivity and specificity.

A chance meeting with Dr. Thomas Stossel, MD at Harvard-affiliated Brigham and Women’s Hospital had steered Dr. Kumar into focusing on SCD. “Initially, we started off working on malaria, because we thought when parasites invaded the cells, it would change their density,” he said, “But when I met Tom Stossel on a panel at the Harvard Medical School, he said, ‘You need to work on sickle cell.’ He’s a hematologist by training and has been working with a nonprofit in Zambia for the past decade, so he’s seen the need from the lack of a diagnostic tool.”

The method design is simple and works by connecting two long-understood principles. First, sickle cell red blood cells (RBCs) are denser than normal RBCs; second, many polymers, when mixed in water, automatically separate into layers ordered by density. Conventional methods to separate cells by density have relied on layering liquids with different density by hand. The new insight was to use the self-forming density layers. “When you mix the polymers with water, they separate just like oil and water,” said Dr. Kumar, “Even if you mix it up, it will still come back to those layers.” When the test was run with infected blood, the results were unmistakable. While healthy RBCs settled in the tubes at specific levels, the dense RBCs from blood infected with sickle cell settled significantly lower. The band of RBCs could clearly be seen by eye.

Next, “We wanted to make the test as simple as possible,” Dr. Kumar explained, “The idea was to make it something you could run from just a finger prick. Because these gradients assemble on their own, that meant we could make them in whatever volume we wanted, even a small capillary tube.” The design they chose is barely larger than a toothpick. In the field, running the test is as simple as uncapping the tube, pricking a patient’s finger, and allowing the blood to wick into the tube.

“There were studies recently that showed in sub-Saharan Africa between 50%-90% of the children born with sickle cell disease die before the age of 5,” said Dr. Kumar, “Whereas in the US people don’t die from this disease as children, they can still live a full life. So my hope is that if this test is effective, it can make [at least] some small dent in those numbers.”

The test is described in the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS), September 2, 2014, online before print.

Related Links:

Harvard University


New
Gold Member
Strep Pneumoniae Rapid Test
Strep Pneumoniae (6503 – 6573)
New
Gold Member
ZIKA Virus Test
ZIKA ELISA IgG
New
Hematology Analyzer
BH-6180
New
Francisella Tularensis Test
Francisella Tularensis Real Time PCR Kit

Print article

Channels

Molecular Diagnostics

view channel
Image: Three newly identified protein biomarkers have the potential to improve diagnostic tools for colorectal cancer (Photo courtesy of Adobe Stock)

New Protein Biomarkers to Improve Diagnostic Tools for Colorectal Cancer

Colorectal cancer is a leading cause of cancer-related deaths globally, and its incidence is expected to rise in the coming decades. This cancer begins when abnormal cells grow uncontrollably in the large... Read more

Microbiology

view channel
Image: The CRISPR-TB Blood Test provides accurate, rapid, and cost-effective diagnosis (Photo courtesy of 123RF)

CRISPR-TB Blood Test to Enable Early Disease Diagnosis and Public Screening

Tuberculosis (TB) continues to be a leading cause of global mortality, with 10.6 million new cases and 1.6 million deaths annually. Diagnosing TB remains difficult, with smear microscopy offering only... Read more

Pathology

view channel
Image: The AI tool can search through data and histology images for much more precise information on cancer treatment effectiveness (Photo courtesy of Shutterstock)

AI Tool Analyzes 30K Data Points Per Medical Imaging Pixel in Cancer Search

A new artificial intelligence (AI)-powered tool can detect cell-level characteristics of cancer by analyzing data from very small tissue samples, some as tiny as 400 square micrometers, equivalent to the... Read more

Industry

view channel
Image: The game-changing immunoassay diagnostics platform delivers results from whole blood sample in 10 minutes (Photo courtesy of SpinChip)

bioMérieux Acquires Norwegian Immunoassay Start-Up SpinChip Diagnostics

bioMérieux (Marcy l’Étoile, France) has agreed to acquire SpinChip Diagnostics (Oslo, Norway), the developer of a game-changing immunoassay diagnostics platform. The small benchtop analyzer is well adapted... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.